Scarica l'app Stockscreener
113.31
2.07%
-2.40
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$115.71
Aprire:
$115.485
Volume 24 ore:
2.15M
Relative Volume:
1.21
Capitalizzazione di mercato:
$22.97B
Reddito:
$5.36B
Utile/perdita netta:
$1.43B
Rapporto P/E:
16.02
EPS:
7.0718
Flusso di cassa netto:
$1.42B
1 W Prestazione:
+0.05%
1M Prestazione:
-8.54%
6M Prestazione:
+19.71%
1 anno Prestazione:
+24.13%
Intervallo 1D:
$112.75
$115.92
Intervallo di 1 settimana:
$112.75
$117.17
Portata 52W:
$84.02
$132.60
Incyte Corp Stock (INCY) Company Profile
Nome
Incyte Corp
Settore
Industria
Telefono
(302) 498-6700
Indirizzo
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, REGN, MRNA, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
113.31 | 22.97B | 5.36B | 1.43B | 1.42B | 7.0718 |
VRTX
Vertex Pharmaceuticals Inc
|
517.49 | 131.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
807.67 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.85 | 79.39B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
869.33 | 54.67B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
370.87 | 41.95B | 5.76B | 514.49M | 1.10B | 4.4813 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-20 | Ripresa | Morgan Stanley | Equal-Weight |
| 2026-08-20 | Iniziato | Canaccord Genuity | Buy |
| 2026-06-22 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
| 2026-05-22 | Iniziato | Bernstein | Mkt Perform |
| 2026-03-16 | Downgrade | Jefferies | Buy → Hold |
| 2026-02-05 | Iniziato | H.C. Wainwright | Buy |
| 2026-01-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-12-08 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-11-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-10-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Iniziato | Barclays | Overweight |
| 2025-06-16 | Aggiornamento | Stifel | Hold → Buy |
| 2025-03-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-18 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Iniziato | UBS | Neutral |
| 2024-10-29 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-01 | Iniziato | Wolfe Research | Outperform |
| 2024-09-18 | Downgrade | Truist | Buy → Hold |
| 2024-07-02 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Iniziato | Deutsche Bank | Hold |
| 2024-04-23 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Iniziato | Jefferies | Buy |
| 2024-02-14 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-11-21 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-25 | Iniziato | Citigroup | Buy |
| 2023-05-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Iniziato | Piper Sandler | Overweight |
| 2022-08-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-07-28 | Iniziato | Wells Fargo | Equal Weight |
| 2022-02-09 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-07-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Iniziato | Truist | Buy |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-06-16 | Iniziato | The Benchmark Company | Hold |
| 2020-05-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Ripresa | William Blair | Outperform |
| 2020-03-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Ripresa | BofA/Merrill | Neutral |
| 2020-01-03 | Reiterato | BMO Capital Markets | Market Perform |
| 2020-01-03 | Downgrade | Mizuho | Buy → Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-10-03 | Iniziato | Mizuho | Buy |
| 2019-09-12 | Iniziato | BMO Capital Markets | Market Perform |
| 2019-09-05 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Iniziato | Credit Suisse | Neutral |
| 2019-05-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Iniziato | Stifel | Hold |
| 2019-04-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Aggiornamento | William Blair | Mkt Perform → Outperform |
Mostra tutto
Incyte Corp Borsa (INCY) Ultime notizie
Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy - Zacks Investment Research
An experimental drug combination showed a 71% response rate in colorectal cancer. - Stock Titan
Incyte Corp. Company & People | INCY - Barron's
Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 - Via TT
Incyte (NasdaqGS:INCY) Stock Price - Simply Wall Street
Incyte Corp. Research & Ratings | INCY - Barron's
Incyte Corp. Advanced Charts | INCY - Barron's
Incyte Corp. Financials | INCY - Barron's
Incyte plans to publish third-quarter results at 7 a.m. Oct. 29, then hold a call at 8. - Stock Titan
Incyte Corporation (INCY) Stock Forecasts - Yahoo Finance
Incyte Corp. Stock Grades | INCY - Barron's
Form 4 Incyte Corporation For: 2 October By Investing.com - Investing.com Canada
Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment - Yahoo Finance
Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment - The Globe and Mail
INCY or TECH: Which Is the Better Value Stock Right Now? - Zacks Investment Research
Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment - TradingView
A legal chief with more than 25 years in pharma and biotech joins MiniMed. - Stock Titan
Mission Bio Showcases Tapestri Across Drug Discovery and Clinical Development at World CDx Summit - Business Wire
About 300 people in the U.S. have a disease that causes bone to form in soft tissues. FDA approves a treatment. - Stock Titan
Incyte will present research on eczema, vitiligo and painful skin conditions in Vienna - Stock Titan
More than 1 million patients have used this skin cream. Partners plan to bring it to Australia. - Stock Titan
Incyte Genomics Inc (INCY) Revenue 2025: $5.1B, up 21.2% - Stock Titan
Incyte Genomics Inc (INCY) Total Assets 2025: $7.0B, up 27.8% - Stock Titan
Incyte Genomics Inc (INCY) EPS 2025: $6.41, up 4173.3% - Stock Titan
Incyte Genomics Inc (INCY) Net Income 2025: $1.3B, up 3846.9% - Stock Titan
Incyte (INCY): 3 Reasons We Love This Stock - Yahoo Finance
Here's How Much $1000 Invested In Incyte 20 Years Ago Would Be Worth Today - Benzinga
Cantor Fitzgerald reiterates Neutral on Incyte stock after conference - Investing.com
Profitable Biotech Incyte Stock Forms Handle Amid Strong Institutional Accumulation - Investor's Business Daily
Cantor Fitzgerald reiterates Neutral on Incyte stock after conference By Investing.com - Investing.com South Africa
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte at Cantor conference: pipeline advances, post-Jakafi plan - investing.com
Incyte Announces Funding of MINJUVI® (tafasitamab) for patients with Relapsed or Refractory Follicular Lymphoma through Ontario's FAST Program - Yahoo Finance
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte at Wells Fargo healthcare conference: pipeline aims to reshape growth - Investing.com India
Incyte at Wells Fargo healthcare conference: pipeline aims to reshape growth - investing.com
Incyte at Wells Fargo healthcare conference: pipeline aims to reshape growth - Investing.com UK
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup - ChartMill
Incyte Corp. (INCY) Peer Comparison – Compare with Others - Value Research
Incyte Corp. (INCY) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Incyte (INCY) Institutional Ownership 2026 $INCY - MarketBeat
Incyte Corp. (INCY) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
2 Profitable Stocks with Impressive Fundamentals and 1 We Brush Off - The Globe and Mail
Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
H.C. Wainwright reiterates Incyte stock rating on Medicaid pricing deal - Investing.com
Incyte to Present at Upcoming Investor Conferences - Yahoo Finance
BMO reiterates Incyte stock rating on CMS pricing agreement - Investing.com
Incyte (INCY) Enters Agreement With CMS to Improve Medicaid Acce - GuruFocus
Incyte Corp Azioni (INCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Incyte Corp Azioni (INCY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| PABLO CAGNONI | Officer |
Oct 15 '26 |
Proposed Sale |
112.71 |
2,642 |
297,780 |
0 |
| CAGNONI PABLO J | President, Global Head of R&D |
Oct 15 '26 |
Sale |
112.71 |
2,642 |
297,780 |
183,200 |
| CAGNONI PABLO J | President, Global Head of R&D |
Sep 15 '26 |
Sale |
120.49 |
23,218 |
2,797,629 |
183,200 |
| PABLO CAGNONI | Officer |
Sep 15 '26 |
Proposed Sale |
120.49 |
23,218 |
2,797,571 |
0 |
| CAGNONI PABLO J | President, Global Head of R&D |
Sep 15 '26 |
Option Exercise |
66.39 |
23,218 |
1,541,331 |
206,418 |
| PABLO CAGNONI | Officer |
Aug 19 '26 |
Proposed Sale |
125.56 |
10,801 |
1,356,190 |
0 |
| CAGNONI PABLO J | President, Global Head of R&D |
Aug 19 '26 |
Sale |
125.56 |
10,801 |
1,356,174 |
183,200 |
| PABLO CAGNONI | Officer |
Aug 12 '26 |
Proposed Sale |
120.04 |
10,803 |
1,296,774 |
0 |
| CAGNONI PABLO J | President, Global Head of R&D |
Aug 12 '26 |
Sale |
120.04 |
10,803 |
1,296,792 |
194,001 |
| PABLO CAGNONI | Officer |
Aug 05 '26 |
Proposed Sale |
122.69 |
10,640 |
1,305,450 |
0 |
1.42%
2.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):